Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ATG-037 by Antengene for Hematological Tumor: Likelihood of Approval
ATG-037 is under clinical development by Antengene and currently in Phase II for Hematological Tumor. According to GlobalData, Phase II...